Table 1.

Accuracy of Direct MTBDRplus and MTBDRsl Testing for Tuberculosis and Phenotypic Second-line Drug Resistance in Sputum of Xpert-Positive Rifampicin-Resistant Patients

Assay		Overall		Smear-Positive		Smear-Negative
		Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
MTBDRplus	Tuberculosis	88 (751/849) 86–90	43 (40/93) 32–53	97 (363/373) 94–98	36 (4/11) 10–69	82 (388/476) 77–84 aP < .001	44 (36/82) 32–54 aP = .635
MTBDRsl	Tuberculosis	82 (696/849) 79–84 bP < .001	51 (47/93) 32–54 bP = .303	93 (347/373) 90–95 bP = .006	73 (8/11) 39–93 bP = .086	73 (349/476) 69–77 aP < .001  bP = .002	48 (39/82) 36–58 aP = .117 bP < .001
	Fluoroquinolones	87 (71/82) 77–93	93 (297/321) 90–96	89 (40/45) 75–96	92 (180/195) 88–96	84 (31/37) 67–93 aP = .105	93 (117/126) 89–98 aP = .855
	Second-line injectable drugs	84 (32/38) 68–93 cP = .720	94 (317/339) 90–95 cP = .820	86 (19/22) 65–97 cP = .001	97 (205/212) 93–98 cP = .108	81 (13/16) 54–95 aP = .011 cP = .821	88 (112/127) 81–93 aP = .002 cP = .052
	Fluoroquinolone and second-line injectable drugs	70 (19/27) 69–98	97 (257/264) 94–98	85 (11/13) 54–98	97(165/169) 94–99	57 (8/14) 28–82 aP = .118	97 (92/95) 91–99 aP = .701

Data are % (n/N), 95% confidence interval. All P values which were statistically significant appeared in bold.

Within-row comparisons between smear statuses.

Within-column comparisons for MTBDRsl vs MTBDRplus.

Within-column comparisons for second-line injectable drugs vs fluoroquinolones.